Salvage reinduction therapy followed by high-dose chemotherapy (HDCT) and auto-SCT is the treatment of choice for fit patients with refractory or relapsed aggressive non-Hodgkin's lymphoma (NHL). We assessed the prognostic value of comorbidity at the time of relapse to predict receipt of auto-SCT and outcome. We analyzed 156 consecutive NHL patients, referred to our center between 1999 and 2007 for salvage reinduction therapy, followed by HDCT and auto-SCT. Comorbidity according to the hematopoietic SCT comorbidity index was scored at relapse and directly before HDCT and auto-SCT. Primary end points were actual receipt of auto-SCT and survival. At relapse, comorbidity scores of 0, 1-2 and X3 were found among 64 (41%), 62 (40%) and 30 (19%) patients, respectively. Ultimately, 95 patients received auto-SCT. Higher comorbidity scores at relapse were associated with significantly less chance of receiving auto-SCT and with inferior OS, independently from secondary age-adjusted International Prognostic Index (sAAIPI) scores. For transplanted patients, OS rates at 5 years were 62, 30 and 17% for relapse comorbidity scores of 0, 1-2 and X3, respectively. In patients with relapsed NHL, comorbidity at relapse is associated with receipt of auto-SCT and subsequent survival independently from the sAAIPI.
Introduction
About 25% of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL) can still be cured by salvage reinduction therapy, followed by myeloablative chemo-and/or radiotherapy and auto-SCT. [1] [2] [3] [4] [5] Unfortunately, this intensive treatment is not suitable for every patient. Selection of patients who might benefit from salvage therapy is difficult, as eligibility depends on diseaseas well as patients' characteristics. The International Prognostic Index (IPI) is highly predictive for response to therapy and survival in aggressive NHL at primary diagnosis. 6, 7 The so-coined secondary age-adjusted IPI (sAAIPI) has extensively shown its predictive value for response to salvage therapy and survival in relapsed or refractory aggressive NHL. 8, 9 Age is left out of this sAAIPI as most patients treated with high-dose chemotherapy (HDCT) are below 60 years. Comorbidity, however, is not included in this prognostic index and has received little attention as a prognostic factor in the auto-SCT setting.
In patients receiving allogeneic SCT, Sorror et al. 10 developed a hematopoietic SCT comorbidity index (HCT-CI) consisting of 17 weighted comorbidity factors. This HCT-CI can predict for 2-year nonrelapse mortality and OS in different hematological malignancies. [10] [11] [12] Few studies have determined whether this comorbidity index can also be applied in predicting outcome in patients receiving HDCT followed by auto-SCT. [13] [14] [15] Incidence and impact of comorbidity may differ substantially between allogeneic and autologous transplant candidates. [16] [17] [18] More importantly, in both autologous and allogeneic settings, comorbidity has only been scored just before receipt of hematopoietic SCT. Therefore, it only predicts outcome in patients who were considered fit enough and survived treatment before transplant conditioning. The initial consideration usually occurs weeks to months before, and data on comorbidity already present at this initial consideration are lacking. The final decision to pursue with transplantation in both the autologous and allogeneic settings is mainly based on the achievement of response to (re)induction therapy and the absence of (therapy-related) additional comorbidity.
We therefore aimed to assess the prognostic value of comorbidity already scored at relapse, that is, at initial consideration before start of salvage treatment, for actual receipt of auto-SCT and subsequent survival among relapsed or refractory aggressive NHL patients.
Patients and methods
All consecutive patients with refractory or relapsed NHL referred for salvage therapy to the University Medical Center Groningen (UMCG) from January 1999 to December 2007 were included. Finally, 160 patients were retrospectively identified using hospital databases. Data could not be retrieved from four patients. Patients were treated according to study (HOVON) or hospital protocols. The majority of patients received salvage reinduction therapy consisting of the DHAP regimen, followed by the VIM regimen (etoposide, ifosfamide and MTX) with or without rituximab (R) (see Figure 1) . 19 After these two cycles of reinduction treatment, patients were restaged according to the (revised) Cheson criteria to evaluate response. 20, 21 Only patients with a complete response (CR) or partial response (PR) received an additional (R)DHAP or (R)VIM cycle and peripheral stem cell harvest. In the absence of important, additional (therapy-related) comorbidity or disease progression, this was followed by the actual autologous transplantation procedure consisting of myeloablative conditioning BCNU, Etoposide, Cytarabine, Melphalan (BEAM) and reinfusion of autologous stem cells. 19 Patients with less than PR after reinduction could receive a second salvage reinduction regimen mainly consisting of Mini-BEAM or ProMace-MOPP in a final effort to induce a response, or were given palliative treatment. When CR or PR was obtained in these patients they were still eligible for transplantation. Data were retrieved from the medical charts using a predefined case report form. Patients were staged according to Cotswolds modification of the Ann Arbor staging system through computed tomography scanning and/or positron emission tomography scanning and BM biopsy performed before the start of reinduction. The sAAIPI was retrospectively calculated on the basis of data available at relapse. Comorbidities according to the HCT-CI were extracted from the laboratory data, functional screening tests and from the medical charts at time of relapse. For comparison, comorbidity scores were also computed at the time of transplantation, that is, before the start of HDCT. The original definitions of the included comorbidities of the HCT-CI have been previously described by Sorror et al.
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The database was closed on 1 July 2008. 
Data analysis
As defined by Sorror et al., 10 comorbidity scores were separated into three groups with HCT-CI scores of 0, 1-2 and X3, respectively. sAAIPI scores were categorized into low-risk disease (scores 0-1) and high-risk disease (scores 2-3), creating comparable numbers in each group.
Actual receipt of auto-SCT was defined as the end point for evaluating eligibility for transplantation, as it depends on the combined result of response to reinduction therapy and the absence of additional important comorbidity. End points for final outcome were early therapy-related mortality and OS. Early therapy-related mortality was defined as mortality during salvage reinduction or within 3 months after auto-SCT not caused by lymphoma progression. OS was defined as the date of the start of salvage reinduction until the date of death from any cause; if no event occurred, patients were censored at the date of last follow-up.
OS rates and survival curves according to relapse comorbidity scores were computed using the method of Kaplan and Meier. The log-rank statistic was used to evaluate differences between subgroups. Differences in sAAIPI and comorbidity scores between subgroups were evaluated using the w 2 -statistic. Subsequently, both indices were tested for their predictive value for actual receipt of auto-SCT by computing odds ratios using univariate and multivariate logistic regression analysis. The prognostic value of relapse comorbidity and sAAIPI scores for early therapy-related mortality and survival was tested by computing hazard ratios (HRs) using Cox proportional hazard regression model in univariate and multivariate analysis.
Results

Patient characteristics
From January 1999 to December 2007, 156 patients with NHL who had failed first-line treatment were identified as candidates for second-line treatment and possible auto-SCT, provided they responded to reinduction therapy. Baseline characteristics and treatment of the patients are shown in Table 1 and Figure 1 , respectively. Most patients had diffuse large B-cell lymphoma. Almost all patients received an (R)DHAP-or (R)VIM-containing regimen during reinduction. Ultimately, 95 patients were transplanted. Of the transplanted patients, 99% had received at least three reinduction cycles. All transplanted patients, except two, received conditioning consisting of BEAM. sAAIPI risk scores at relapse were significantly lower in patients who were ultimately transplanted compared with those who were not (Po0.001).
Comorbidity
Frequencies of comorbidities and corresponding scores are listed in Table 2 . Mild hepatic comorbidities were most Table 1 Baseline characteristics of patients with relapsed or primary refractory NHL who were referred for salvage therapy frequently observed, whereas none of the patients had active infection during start of reinduction therapy. Nontransplanted patients had significantly higher relapse comorbidity scores (P ¼ 0.002) compared with the transplanted patients. For comparison, comorbidity scores for the transplanted patients calculated at time of actual transplantation are also demonstrated. Comorbidity factors based on laboratory values observed at relapse were not always observed among the same patients at transplantation. For patients who were transplanted, no differences were observed in frequencies of comorbidity at the time of relapse and comorbidity scored at the time of transplantation, except for comorbidities based on laboratory values and weight. As a result, only minor changes in HCT-CI scores were observed at transplantation (mean comorbidity score 0.93) as compared with scores at relapse (mean comorbidity score 0.95).
Response to salvage reinduction After two cycles of reinduction chemotherapy, 99 (63%) patients had responsive disease (PR or CR) qualifying for HDCT and auto-SCT ( Figure 1 ). Of these patients, 87 received a third cycle of reinduction chemotherapy, and subsequent HDCT and auto-SCT. Of the 62 patients with less than PR, including those who initially responded but progressed before transplant, 35 received a second salvage reinduction regimen. A final CR or PR was obtained in 11 of these patients and 8 ultimately received HDCT and auto-SCT. Patients who were offered a second salvage reinduction regimen had significantly lower comorbidity scores at time of initial relapse (HCT-CI scores of 0, 1-2 and X3 among 15, 16 and 4 patients, respectively) compared with the patients who were not candidates for a second salvage reinduction regimen (HCT-CI scores of 0, 1-2 and X3 among 5, 13 and 9 patients, respectively) (P ¼ 0.04). Thus, 110 patients had responsive disease qualifying for HDCT and auto-SCT. Reasons for not proceeding to transplantation despite having responsive disease were progressive disease just before auto-SCT (n ¼ 11), failure to harvest stem cells (n ¼ 3) and comorbidity (n ¼ 1).
Overall mortality and early therapy-related mortality Out of 156 patients 109 (70%) have died; 51 (54%) transplanted and 58 (95%) nontransplanted patients. Median follow-up was 22 months (range 3-108 months) for transplanted patients and 5 months for nontransplanted patients (range 0-59). OS at 5-year follow-up was 49% for transplanted patients and 2% for nontransplanted patients. The most frequent cause of death was lymphoma progression or relapse in both transplanted (84%) and nontransplanted patients (86%) ( Table 3) . Early therapy-related mortality was observed in six patients during reinduction and in seven patients during admission for auto-SCT or within 3 months after transplant. There were no significant differences in relapse comorbidity scores among the 13 patients with early therapy-related mortality compared with the other patients.
Predicting receipt of auto-SCT Among patients with low-risk comorbidity (relapse HCT-CI 0), 49/64 (77%) proceeded to transplant, whereas 33/62 (53%) of the patients with intermediate-risk comorbidity (relapse HCT-CI 1-2) and 13/30 (43%) of the patients with high-risk comorbidity (relapse HCT-CI X3) proceeded to transplant. Both increasing relapse comorbidity scores and high sAAIPI scores were associated with not receiving transplantation (Table 4) . Relapse HCT-CI scores of 1-2 and X3 corresponded with odds ratios for not receiving auto-SCT of 2.9 and 4.3, respectively. High-risk disease according to the sAAIPI corresponded with an odds ratio of 4.4 for not receiving auto-SCT. In multivariate analysis, both relapse comorbidity and sAAIPI remained significant in predicting receipt of transplant. Comorbidity was equally predictive among patients with low-and high-risk sAAIPI. Age 460 years or number of extranodal sites at time of relapse were not related to receipt of transplant.
Predicting survival
In the transplanted patients, relapse HCT-CI scores of 1-2 and X3 corresponded with HRs for OS of 2.4 and 2.5, respectively (Table 5) . No significant differences in survival were found between relapse HCT-CI scores of 1-2 and X3.
In the transplanted patients, sAAIPI was no longer significant for OS. Among all patients, comorbidity could predict OS independently from sAAIPI (Table 5) , with comorbidity performing equally in both low-and high-risk sAAIPI (HR for OS of 2.1 for relapse comorbidity X1 in both high-and low-risk sAAIPI; data not shown). Age 460 years at time of relapse, numbers of extranodal sites or having only a PR on reinduction therapy did not influence survival.
Survival curves according to relapse comorbidity are depicted in Figure 2 . OS at 5 years for all patients was 44% for relapse HCT-CI score 0, 18% for scores 1-2 and 7% for scores X3 (log-rank, Po0.001). For the transplanted patients, relapse HCT-CI score of 0 corresponded with 5-year OS rates of 62%, scores of 1-2 with 30% and X3 with 17% survival (log-rank, P ¼ 0.006).
Discussion
In this study of 156 consecutive patients with relapsed or primary refractory aggressive NHL, we showed that the HCT-CI, calculated at time of relapse, can predict for receipt of and survival after auto-SCT, independently from sAAIPI scores.
Our single center-derived cohort was comparable with patients with relapsed or refractory aggressive lymphoma reported by others, with comparable transplant outcomes and predictive value of sAAIPI (Table 4) . [6] [7] [8] Recently, the influence of comorbidity on outcome after autologous transplantation has also been reported by others. [13] [14] [15] However, none of these studies have compared comorbidity directly with sAAIPI scores or analyzed its predictive value for eligibility for transplantation. One of these studies found that comorbidity was not predictive for survival (HR 0.7 for HCT-CI scores 42), but this study was performed among elderly patients only. 13 Another study measured comorbidity according to the less-sensitive Charlson Comorbidity Index and found that the presence of comorbidity corresponded with diminished survival (log-rank, P ¼ 0.016). 14 Sorror et al. 15 analyzed the influence of comorbidity in a mixed group of lymphoma patients with various conditioning regimens and found that especially HCT-CI scores X3 predicted for diminished survival (HR 2.9).
In contrast to these studies, we used comorbidity at relapse both in patients who were finally transplanted and in patients who did not receive auto-SCT. Therefore, comorbidity was not only applied to predict outcome among patients actually receiving auto-SCT but also to predict eligibility for transplantation, including response to reinduction therapy. Furthermore, patients received uniform treatment as far as the reinduction regimen and conditioning regimen were concerned.
As in other comparable studies, one of the limitations of our study is its retrospective nature. Therefore, some comorbidity factors might have been missed, when not routinely tested or adequately recorded in the medical charts. For instance, this might be the case for pulmonary comorbidity, one of the factors with high prevalence in studies concerning allogeneic transplantation. If pulmonary function tests would have been routinely performed, more pulmonary comorbidity might have been observed and the prognostic value of comorbidity could have been even more pronounced. Repeated testing might have detected a possible change in pulmonary function between time of relapse and time of transplantation due to treatment toxicity and subsequently altered comorbidity scores at time of transplantation. Furthermore, it is important to realize that some patients were not included in our analysis because they were never referred to our center for salvage therapy because of obvious exclusion criteria. However, comorbidity still had high predictive value in this cohort and its predictive value would have been even more distinct without this preselection. Finally, numbers of patients in our cohort were too low to perform an analysis of individual comorbidity factors. The sAAIPI has extensively proved its value in predicting response to reinduction therapy and final outcome in patients with relapsed aggressive NHL. [7] [8] [9] In our cohort, high-risk sAAIPI was highly predictive for both not receiving auto-SCT and survival. Probably because of the fact that only 5 out of 22 patients with sAAIPI scores of 3 ultimately received transplantation, the sAAIPI was no longer predictive for survival among the transplanted patients.
Response to reinduction therapy is the main factor determining receipt of transplant. Besides failure of response to reinduction therapy, serious comorbidity might also be an exclusion factor to proceed to transplant. Although only one patient did not proceed to transplant because of comorbidity in our cohort, presence of comorbidity was highly associated with not receiving auto-SCT independently from the sAAIPI. An explanation for this is that patients with high comorbidity scores were less likely to receive a second salvage reinduction regimen when not responding to the first salvage reinduction regimen in our cohort. Patients with high comorbidity therefore had less chance of response on reinduction therapy. Thus, response to reinduction therapy was influenced by both disease factors (sAAIPI) and comorbidity.
It is not easy to provide a biological explanation for the fact that comorbidity can predict for OS. One might imagine that comorbidity predicts early therapy-related mortality. Although events were rare and not enough to tease out the real impact of comorbidity on therapy-related mortality, this could not explain the predictive value of comorbidity on survival in our cohort. Therefore, one might question whether comorbidity, scored at initial relapse, is associated with lymphoma progression after auto-SCT, because the major cause of death even in the transplanted patient group was progressive lymphoma. Indeed, the 22 patients who did not reach a CR and progressed after auto-SCT had significantly higher comorbidity scores at relapse than the 66 patients in remission after auto-SCT (P ¼ 0.01). Among the 66 patients with a CR after auto-SCT, there were no significant differences in relapse comorbidity scores between the 29 patients with a relapse after auto-SCT and the 37 patients who remained in remission. Given the fact that comorbidity might predict for achievement of CR, comorbidity might thus be dependent on other unfavorable lymphoma-related prognostic factors. However, the prognostic value of comorbidity was independent from the sAAIPI risk profile, which is presently the best lymphoma-related prognostic marker available.
Another explanation could be that patients with high comorbidity scores might have received less chemotherapy and therefore would have been more at risk for an insufficient response. Again, this seems unlikely, as 99% of the transplanted patients received at least three cycles of reinduction chemotherapy and received the same HDCT regimen. Another hypothesis is that patients with high comorbidity were not offered additional treatment when they experienced relapse post transplant. In our center, however, patients who experience early relapse after transplant are generally offered palliative treatment only.
Finally, some comorbidity factors might have been manifestations of tumor extensiveness or activity. However, most factors in the comorbidity score are factors derived from medical conditions already present before the diagnosis of lymphoma. Only factors derived from current laboratory values, such as hepatic or renal comorbidity, might have been influenced by tumor extensiveness. In this theory, there is a thin line between morbidity and comorbidity.
Performance status is one of the factors included in the sAAIPI and its relation with comorbidity is interesting as both parameters determine physical constitution. Whereas performance status is based on daily activities and self-care, the comorbidity index is an extensive, organ-specific index. Both indices cannot be seen totally distinct from each other, as comorbidity can also seriously influence performance status. However, comorbidity and performance status were independent predictors for receipt of transplant and survival in our autologous transplant cohort. This independent predictive value of comorbidity and performance score has also been reported among patients undergoing allo-SCT. 22, 23 In conclusion, response to reinduction therapy is the main factor determining receipt of auto-SCT in patients with relapsed or refractory aggressive NHL. Comorbidity scored at relapse was associated with less chance of response to salvage reinduction therapy independently from the sAAIPI and therefore with less chance on receipt of auto-SCT. Furthermore, comorbidity at relapse could predict for survival after auto-SCT, independently from the sAAIPI. Determination of both comorbidity at time of relapse and the sAAIPI might improve selection of suitable patients for salvage treatment.
